Background:  NY-ESO-1, also known as autoimmunogenic cancer/testis antigen, is a tumor-specific shared antigen with distinctive immunogenicity. NY-ESO-1 is a member of the cancer/testis (CT) family of human tumor-associated antigens. NY-ESO-1 is an attractive candidate tumor antigen for the development of immunotherapy for a wide variety of cancers. NY-ESO-1 is expressed in multiple types of tumors, but its normal tissue distribution is primarily limited to testis and ovary. In addition, NY-ESO-1 elicits frequent antibody responses in cancer patients that are accompanied by strong CD8+ T cell responses against HLA-A2-restricted epitopes. Therefore, both humoral and cellular immune responses can be mounted against NY-ESO-1.

Description: Rabbit polyclonal to CTAG1B

Immunogen: KLH conjugated synthetic peptide derived from CTAG1B

Specificity:  ·Reacts with Human, Mouse and Rat.

·Isotype: IgG

Application:  ·Western blotting: 1/100-500. Predicted Mol wt: 18 kDa;

·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;

·Immunocytochemistry/Immunofluorescence: 1/100;

·Immunoprecipitation: 1/50;

·ELISA: 1/500;

·Optimal working dilutions must be determined by the end user.